Quanterix (QTRX) Aktievy
Quanterix Corporation, ett biovetenskapligt företag i Nordamerika, Europa, Mellanöstern, Afrika och Asien och Stillahavsområdet. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
QTRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Quanterix Corporation Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$2.52 |
| 52 veckors högsta | US$8.77 |
| 52 veckors lägsta | US$2.40 |
| Beta | 1.15 |
| 1 månads förändring | -23.64% |
| 3 månaders förändring | -57.65% |
| 1 års förändring | -47.61% |
| 3 års förändring | -88.07% |
| 5 års förändring | -95.09% |
| Förändring sedan börsintroduktionen | -85.58% |
Senaste nyheter och uppdateringar
Recent updates
Uppdatering av berättelse • May 01
QTRX: Alzheimer’s Blood Test Progress Will Support Long Term Upside Potential
Analysts have reduced their price target on Quanterix by $2, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that were reflected in recent Street research, including a $4 reduction highlighted by Canaccord. Analyst Commentary Recent research around the target cut focuses less on a single headline number and more on how updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E compare with execution risk.
Uppdatering av berättelse • Apr 16
QTRX: Expanding Alzheimer’s Blood Screening Access Will Support Stronger Future Earnings Power
Narrative Update on Quanterix The latest analyst price target on Quanterix has been revised in line with updated assumptions for discount rate, revenue growth, profit margin, and future P/E, as analysts adjust their models to reflect a slightly different balance of growth expectations and risk. What's in the News Lucent Diagnostics partnered with Life Line Screening to offer a non-invasive blood based biomarker test for Alzheimer's disease nationally, with programs already underway in Florida, California, and Texas, using a mobile model that reaches community centers, churches, and senior centers (Client Announcements).Seeking Alpha • Apr 10
Quanterix: No Green Shoots
Summary Quanterix Corporation shares have halved in 2025, reflecting persistent losses and underwhelming sales momentum despite a substantial net cash position. Quanterix's 2026 guidance signals flat revenues ($169–$174M) and gross margins in line with 2025, with cash flow break-even targeted in the year's second half. Cost synergies from the Akoya deal are largely realized, but QTRX operating losses remain significant, and sequential revenue or margin gains are lacking. QTRX stock's valuation is historically cheap at 0.3x sales, yet repeated disappointments and missed promises keep investor sentiment extremely cautious. Read the full article on Seeking AlphaUppdatering av berättelse • Apr 02
QTRX: Alzheimer’s Blood Test Advancements Will Drive Strong Long Term Upside
Analysts made a modest adjustment to their price target on Quanterix, trimming it by $0.10 to reflect slightly lower assumptions for revenue growth and profit margins, along with a somewhat higher expected future P/E and discount rate. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for a multi analyte, algorithmic blood test intended to aid in evaluating patients with cognitive symptoms for possible Alzheimer’s disease.Uppdatering av berättelse • Mar 19
QTRX: Alzheimer’s Blood Test Progress Will Support Stronger Earnings Power Ahead
Analysts have nudged their price target on Quanterix to $8.00 from $8.00, reflecting slightly updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, without a clear shift in overall valuation stance. What's in the News Quanterix issued earnings guidance for 2026, with expected revenues between US$169 million and US$174 million, providing a concrete management view of the top line for that year (Corporate guidance).Uppdatering av berättelse • Mar 04
QTRX: Alzheimer’s Blood Test Progress Will Shape Favorable Long Term Outlook
Analysts have made modest adjustments to their price targets on Quanterix, reflecting updated views on discount rates, revenue growth expectations, profit margins, and future P/E assumptions, while keeping their overall fair value estimate broadly in line with prior levels. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for a multi analyte algorithmic blood test for Alzheimer's disease, supported by clinical evidence in over 1,800 symptomatic patients across three cohorts.
Uppdatering av berättelse • Feb 18
QTRX: Alzheimer’s Blood Test Progress Will Drive Long-Term Upside Potential
Analysts have lifted their price target on Quanterix to $7.00 from $7.00, reflecting slight tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that leave their overall valuation view essentially unchanged. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. FDA for a multi analyte algorithmic blood test for Alzheimer's disease, aiming to support evaluation of patients with cognitive symptoms using a non invasive, high performance diagnostic tool (Key Developments).Uppdatering av berättelse • Feb 04
QTRX: New Leadership And Neurodegenerative Pipeline Will Balance Near Term Multiple Risks
Narrative Update on Quanterix Analysts have lifted their fair value estimate for Quanterix from US$6.00 to US$7.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that collectively support a higher long term price target range. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for a multi analyte algorithmic blood test for Alzheimer’s disease, aimed at helping identify whether symptomatic patients are likely to have amyloid brain plaques using its Simoa technology and a panel of five biomarkers (p Tau 217, Ab42, Ab40, GFAP, NfL), supported by clinical evidence from more than 1,800 patients (Key Developments).Uppdatering av berättelse • Jan 21
QTRX: Future Leadership And Biomarker Data Will Shape Balanced 2025 Outlook
Analysts have raised their price target on Quanterix to 7.33 from 6.00 previously, reflecting updated fair value estimates based on adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News The board has appointed Everett Cunningham as Chief Executive Officer, effective January 19, 2026.Analysartikel • Jan 10
Market Still Lacking Some Conviction On Quanterix Corporation (NASDAQ:QTRX)
Quanterix Corporation's ( NASDAQ:QTRX ) price-to-sales (or "P/S") ratio of 2.9x might make it look like a buy right now...Uppdatering av berättelse • Jan 07
QTRX: Multiple Sclerosis Biomarker Validation Will Support Stronger Earnings Power Ahead
Analysts have raised their price target on Quanterix to US$8.00 from US$7.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News A study published in the journal Brain validates multiplexed Simoa assays for GFAP and NfL as a complementary approach for monitoring Multiple Sclerosis disease activity and progression.Uppdatering av berättelse • Dec 23
QTRX: Elevated Multiple And Higher Discount Rate Will Pressure Prospects
Analysts have raised their price target on Quanterix by approximately 20 percent to around 6 dollars per share, citing a modestly higher fair value estimate, slightly stronger long term profitability assumptions, and a willingness to apply a richer future earnings multiple, despite trimming revenue growth expectations and using a higher discount rate. What's in the News Publication of a landmark Brain journal study validating Quanterix Simoa assays for GFAP and NfL as a complementary, two biomarker approach for comprehensive Multiple Sclerosis disease monitoring, covering both acute inflammatory activity and slow progression (Key Developments) Evidence that elevated serum GFAP levels are significantly associated with higher risk of progression independent of relapse activity, highlighting a major unmet therapeutic need in MS and expanding the clinical utility of Quanterix assays (Key Developments) Creation of large Simoa-based normative reference databases for GFAP and NfL, incorporating age, sex, and BMI, alongside a free online interpretive tool to support more precise, individualized MS risk assessment (Key Developments) Updated 2025 revenue guidance of 130 million to 135 million dollars, implying pro forma revenue of 165 million to 170 million dollars for the year if combined operations are assumed, with an expected GAAP gross margin of 45 percent to 47 percent (Key Developments) Valuation Changes Fair Value Estimate has risen modestly from approximately 5 dollars to 6.0 dollars per share.Analysartikel • Aug 28
Market Cool On Quanterix Corporation's (NASDAQ:QTRX) Revenues Pushing Shares 29% Lower
Quanterix Corporation ( NASDAQ:QTRX ) shares have had a horrible month, losing 29% after a relatively good period...Uppdatering av berättelse • Aug 15
Biomarker Diagnostics And Proteomics Will Shape Future Markets
Analysts maintain a cautious stance on Quanterix due to near-term uncertainty, weak Q2 results, and biopharma sector headwinds, keeping the price target unchanged at $6.00. Analyst Commentary Downgrade reflects a lack of near-term visibility and absence of clear catalysts to drive the stock higher.Analysartikel • Aug 10
Quanterix Corporation (NASDAQ:QTRX) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
It's shaping up to be a tough period for Quanterix Corporation ( NASDAQ:QTRX ), which a week ago released some...Analysartikel • Jun 13
Even With A 33% Surge, Cautious Investors Are Not Rewarding Quanterix Corporation's (NASDAQ:QTRX) Performance Completely
Those holding Quanterix Corporation ( NASDAQ:QTRX ) shares would be relieved that the share price has rebounded 33% in...Analysartikel • Apr 08
Market Cool On Quanterix Corporation's (NASDAQ:QTRX) Revenues Pushing Shares 30% Lower
Unfortunately for some shareholders, the Quanterix Corporation ( NASDAQ:QTRX ) share price has dived 30% in the last...
Ny berättelse • Mar 28
Simoa ONE Platform Will Revitalize Immunology And Oncology Markets
Strategic product expansion and key acquisitions could significantly enhance market reach and revenue potential in immunology and oncology markets.Seeking Alpha • Jan 11
Quanterix: Why Pursuing A Big Deal For Akoya?
Summary Quanterix's IPO in 2017 was highly speculative, with its Simoa technology promising ultra-sensitive diagnostics but accompanied by substantial operating losses and continued dilution. Despite revenue growth to $121 million in 2023, Quanterix still faces significant losses, and expects a $25-$30 million cash burn in 2024. Slower growth in 2024, compliance issues, and a controversial acquisition of Akoya Biosciences have pressured shares, raising concerns about combining two loss-making entities. The acquisition news led to a 20% share price drop, prompting a cautious outlook despite the potential synergies and growing revenue base. Read the full article on Seeking AlphaAnalysartikel • Nov 07
Even With A 36% Surge, Cautious Investors Are Not Rewarding Quanterix Corporation's (NASDAQ:QTRX) Performance Completely
Quanterix Corporation ( NASDAQ:QTRX ) shares have had a really impressive month, gaining 36% after a shaky period...Analysartikel • Oct 17
We're Hopeful That Quanterix (NASDAQ:QTRX) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 26
Quanterix Corporation: Still Struggling To Gain Traction
Summary Today, we revisit Quanterix Corporation, which provides ultra-sensitive digital assay platforms for detecting protein biomarkers in healthcare. The company has a pristine balance sheet with some $300 million in net cash on it. Quanterix Corporation is also seeing steady revenue growth. Unfortunately, the firm is making little progress on the profitability front but is pushing further into early Alzheimer's detection. Will that enable Quanterix to “turn the corner”? An updated analysis follows in the paragraphs below. Read the full article on Seeking AlphaAnalysartikel • Aug 15
Take Care Before Jumping Onto Quanterix Corporation (NASDAQ:QTRX) Even Though It's 26% Cheaper
To the annoyance of some shareholders, Quanterix Corporation ( NASDAQ:QTRX ) shares are down a considerable 26% in the...Analysartikel • Jun 27
Positive Sentiment Still Eludes Quanterix Corporation (NASDAQ:QTRX) Following 25% Share Price Slump
Unfortunately for some shareholders, the Quanterix Corporation ( NASDAQ:QTRX ) share price has dived 25% in the last...Analysartikel • Apr 14
Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues
Quanterix Corporation ( NASDAQ:QTRX ) shares have had a horrible month, losing 31% after a relatively good period...Analysartikel • Apr 05
Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Analysartikel • Mar 03
Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year
Investors in Quanterix Corporation ( NASDAQ:QTRX ) had a good week, as its shares rose 8.6% to close at US$27.00...Aktieägarnas avkastning
| QTRX | US Life Sciences | US Marknad | |
|---|---|---|---|
| 7D | -12.5% | 1.6% | -0.3% |
| 1Y | -47.6% | 7.1% | 26.7% |
Avkastning vs industri: QTRX presterade sämre än US Life Sciences branschen som gav 7.1 % under det senaste året.
Avkastning vs Marknaden: QTRX presterade sämre än US marknaden som gav 26.7 % under det senaste året.
Prisvolatilitet
| QTRX volatility | |
|---|---|
| QTRX Average Weekly Movement | 10.5% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: QTRX har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: QTRX s veckovolatilitet ( 10% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2007 | 450 | Everett Cunningham | www.quanterix.com |
Quanterix Corporation, ett life science-företag i Nordamerika, Europa, Mellanöstern, Afrika och Asien och Stillahavsområdet. Företaget erbjuder HD-X-instrumentet, en plattform för proteindetektion, och SR-X-instrumentet som gör det möjligt för forskare att använda Simoa-detektion i ett utökat antal applikationer. Företaget erbjuder också SP-X-instrumentet som bygger på Simoa planar array-teknik för mätning av multiplexa kemiluminescerande immunoassays.
Quanterix Corporation Sammanfattning av grunderna
| QTRX grundläggande statistik | |
|---|---|
| Börsvärde | US$118.24m |
| Vinst(TTM) | -US$104.19m |
| Intäkter(TTM) | US$144.98m |
0.8x
P/S-förhållande-1.1x
P/E-förhållandeÄr QTRX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| QTRX resultaträkning (TTM) | |
|---|---|
| Intäkter | US$144.98m |
| Kostnad för intäkter | US$79.29m |
| Bruttovinst | US$65.69m |
| Övriga kostnader | US$169.87m |
| Intäkter | -US$104.19m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -2.21 |
| Bruttomarginal | 45.31% |
| Nettovinstmarginal | -71.86% |
| Skuld/egenkapitalförhållande | 0% |
Hur har QTRX utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/20 09:52 |
| Aktiekurs vid dagens slut | 2026/05/20 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Quanterix Corporation bevakas av 7 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |
| Matthew Sykes | Goldman Sachs |